Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 17 2022 - 7:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing SINTAX™ medicines as a new
modality of orally delivered treatments for inflammatory disease,
today announced that it will host a conference call and live
webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its
fourth quarter and full year 2021 financial results and discuss
business highlights.
To access the live conference call, please dial 866-795-3242
(domestic) or 409-937-8909 (international) and refer to conference
ID 6076311. A live webcast of the event will also be available
under “News and Events” in the Investors section of Evelo's website
at http://ir.evelobio.com. The archived webcast will be available
on Evelo's website approximately two hours after the completion of
the event and will be available for 30 days following the call.
About Evelo BiosciencesEvelo Biosciences is a
clinical stage biotechnology company developing orally delivered
product candidates that are designed to act on the small intestinal
axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a
central role in governing the immune, metabolic, and neurological
systems. The Company’s first product candidates are pharmaceutical
preparations of single strains of microbes selected for their
potential to offer defined pharmacological properties. Evelo’s
therapies have the potential to be effective, safe, and affordable
medicines to improve the lives of people with inflammatory
diseases.
Evelo currently has three product candidates in
development: EDP1815, EDP1867, and EDP2939 for the treatment of
inflammatory diseases. Evelo is advancing additional product
candidates in other disease areas.
For more information, please visit
www.evelobio.com and engage with Evelo on LinkedIn.
ContactsInvestors:Kendra
Sweeney, 239-877-7474ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Sep 2023 to Sep 2024